



Virtual
**2021 IASL
Annual Conference**

Liver Disease in the 21st Century : A Global Perspective

July 16-17, 2021 | www.iasliver.org

Scientific Highlights

- Unresolved Issues in Hepatitis B
- HCV Cure - Are We Done?
- Design of Clinical Trials for HBV Cure
- Challenges Hepatitis and Liver Failure
- Emerging Issues in the Era of COVID-19
- Global Perspectives on Liver Disease
- Academic Career Workshop

- Portal Hypertension in the 21st Century
- Complications of Cirrhosis
- Non-Invasive Assessment of Liver Fibrosis: A Case Based Approach
- Design of Clinical Trials for NAFLD
- Management in NAFLD
- Alcoholic Liver Disease in the 21 Century

- Joint Session 1: IASL & Africa/Middle East
- Joint Session 2: IASL & South America
- Joint Session 3: IASL & The Korean Liver Cancer Association
HCC - Recent Advances in Prevention and Treatment



IASL International Association for
the Study of the Liver (IASL)

Virtual

2021 IASL Annual Conference

Liver Disease in the 21st Century : A Global Perspective



July 16-17, 2021 | www.iasliver.org

PROGRAM AT A GLANCE

DAY 1. Thursday, July 15: North & South America Friday, July 16: Oceania / Asia / Africa / Europe		DAY 2. Friday, July 16: North & South America Saturday, July 17: Oceania / Asia / Africa / Europe		
	ROOM 1	ROOM 2	ROOM 1	ROOM 2
07:00				
08:00			Joint Session 2 IASL & South America (07:10-08:50)	
09:00	Session 1 Unresolved Issues in Hepatitis B (09:00-10:40)	Session 2 Global Perspectives on Liver Disease (09:00-10:40)	Session 9 Portal Hypertension in the 21st Century (09:00-10:40)	Session 10 Non-Invasive Assessment of Liver Fibrosis: A Case Based Approach (09:00-10:40)
10:00				
11:00	Session 3 HCV Cure - Are We Done? (10:50-12:30)	Session 4 Design of Clinical Trials for HBV Cure (10:50-12:20)	Session 11 Complications of Cirrhosis (10:50-12:30)	
12:00				
13:00	Lunch Break (12:30-13:10)		Lunch Break (12:30-13:30)	
14:00	IASL Symposium & IASL General Meeting			Joint Session 3 IASL & KLCA HCC - Recent Advances in Prevention and Treatment (13:00-15:20)
15:00	Session 5 Emerging Issues in the Era of COVID-19 (14:00-15:40)	Session 6 Academic Career Workshop (14:00-15:40)	Session 12 Management in NAFLD (13:30-15:10)	
16:00			Presidential Lecture (15:20-15:50)	
17:00	Session 7 Challenges Hepatitis and Liver Failure (15:50-17:30)	Session 8 Design of Clinical Trials for NAFLD (15:50-17:30)	Session 13 Alcoholic Liver Disease in the 21 Century (16:00-17:40)	
18:00	Joint Session 1 IASL & Africa/Middle East (17:40-19:20)		Wrap-Up & Closing (17:40-18:00)	
19:00				
20:00				* GMT+09:00 (Seoul, Tokyo)

REGISTRATION GUIDELINES

Category	Registration Fee
Member	USD 50.00
Resident, Trainee, Fellow, Researcher, or Others	USD 30.00
Non-Member, Healthcare Professional	USD 80.00

The registration fee includes the entrance to all lectures and sessions. The entire program will be available for 60 days for the registrants following the completion of the conference.

DAY 1

Thursday, July 15: North & South America
Friday, July 16: Oceania / Asia / Africa / Europe

ROOM 1

GMT+09:00 (Seoul, Tokyo)

Session 1 Unresolved Issues in Hepatitis B		
09:00-09:20	Immune Tolerance - Does It Exist and Shall We Treat?	<i>Hye Won Lee (Yonsei University, Korea)</i>
09:20-09:40	How to Define and Manage Inactive Carriers?	<i>Jia Horng Kao (National Taiwan University, Taiwan)</i>
09:40-10:00	Can Biomarkers Guide Stopping NA?	<i>Jinlin Hou (Southern Medical University, China)</i>
10:00-10:20	Prophylaxis for Anti-HBc Positive Patients on Immunosuppression	<i>Rajender Reddy (University of Pennsylvania, USA)</i>
10:20-10:40	Discussion	
10:40-10:50	Break	
Session 3 HCV Cure - Are We Done?		
10:50-11:10	Is DAA for All HCV-Related HCC Patients - A Call for Expanded Use and the Point of "No Return"	<i>Norah Terrault (Keck School of Medicine of USC, USA)</i>
11:10-11:30	DAA Treatment in Asia Pacific Region and Its Impact on Clinical Outcome	<i>Sang Hoon Ahn (Yonsei University, Korea)</i>
11:30-11:50	HCV Treatment in Special Populations	<i>Ed Gane (The University of Auckland, New Zealand)</i>
11:50-12:10	Roadmap to HCV Elimination in 2030	<i>Nobuyuki Enomoto (University of Yamanashi, Japan)</i>
12:10-12:30	Discussion	
12:30-13:10	Lunch Break	
IASL Opening Ceremony & General Meeting		
13:10-13:25	Opening Remarks	<i>Representative of IASL/EASL/AASLD/WGO</i>
13:25-13:35	Past of IASL	<i>Samuel Lee, Past President</i>
13:35-13:45	General Meeting: IASL Report	<i>Markus Peck, Secretary General</i>
13:45-13:50	Future of IASL	<i>Markus Peck, President-Elect</i>
13:50-14:00	Break	
Session 5 Emerging Issues in the Era of COVID-19		
14:00-14:20	Telemedicine in Resource Limited Setting	<i>Marco Arrese (Pontificia Universidad Católica de Chile, Chile)</i>
14:20-14:40	COVID Vaccine for Liver Patients	<i>Raymond Chung (Harvard Medical School, USA)</i>
14:40-15:00	Significance of Liver Injury in COVID-19 Patients	<i>Qin Ning (Huazhong University of Science and Technology, Hong Kong, China)</i>
15:00-15:20	Immunologic Approach for COVID-19	<i>Mario Mondelli (University of Pavia, Italy)</i>
15:20-15:40	Discussion	
15:40-15:50	Break	
Session 7 Challenges in Hepatitis and Liver Failure		
15:50-16:10	Acute Hepatitis E - Challenges in Diagnosis and Management	<i>Heiner Wedemeyer (Hannover Medical School, Germany)</i>
16:10-16:30	Diagnostic Dilemma of Drug Induced Liver Injury	<i>Alexander Gerbes (Ludwig-Maximilian-University of Munich, Germany)</i>
16:30-16:50	Hepatitis Delta - A Treatable Disease?	<i>Cihan Yurdaydin (University of Ankara Medical School, Turkey)</i>
16:50-17:10	Acute on Chronic Liver Failure - When to Consider Liver Transplantation?	<i>Saeed Hamid (The Aga Khan University, Pakistan)</i>
17:10-17:30	Discussion	
17:30-17:40	Break	
Joint 1 IASL & Africa and Middle East		
17:40-17:55	HCV Elimination on Target - Lessons from Egypt	<i>Imam Waked (National Liver Institute, Egypt)</i>
17:55-18:05	HCV - Reaching 2030 - Yes Rwanda Can!	<i>Sabin Nanzimana (Rwanda Biomedical Center, Rwanda)</i>
18:05-18:20	Mapping NAFLD Burden in the Middle East	<i>Mohamed Elkassas (Helwan University, Egypt)</i>
18:20-18:30	MAFLD in SSA - Impending Doom or Unique Opportunity?	<i>Mark Sonderup (University of Cape Town, South Africa)</i>
18:30-18:40	Upscaling HBV Care in SSA - Can We Simply Do It?	<i>Gibril Ndow (MRC Unit The Gambia at LSHTM, Gambia)</i>
18:40-18:50	HCC in SSA - Can We Do Better ?	<i>Edith Okeke (University of Jos, Nigeria)</i>
18:50-19:00	Project ECHO and NextGen Liver Education in SSA	<i>Wendy Spearman (University of Cape Town, South Africa)</i>
19:00-19:20	Discussion	

DAY 1 Thursday, July 15: North & South America
Friday, July 16: Oceania / Asia / Africa / Europe

Session 2 Global Perspectives on Liver Disease

09:00-09:20	How to Lead a Team for Big Data Research?	<i>Grace Wong (The Chinese University of Hong Kong, China)</i>
09:20-09:40	How to Overcome Pitfalls in Observational Studies	<i>Young Suk Lim (University of Ulsan, Korea)</i>
09:40-10:00	AI Cutting-Edge Developments in Highly Developed Systems	<i>Yock Yan Dan (National University Health System, Singapore)</i>
10:00-10:15	Personalized Medicine in Liver Diseases: "Present and Future"	<i>Joost Drenth (Radboud University, Netherlands)</i>
10:15-10:40	Discussion	
10:40-10:50	Break	

Session 4 Design of Clinical Trials for HBV Cure

10:50-11:15	Early Response Indicators of Direct Antiviral Agents	<i>Harry Janssen (University of Toronto, Canada)</i>
11:15-11:40	Immunological Correlates of Response to Treatments	<i>Antonio Bertoletti (Duke-NUS Medical School, Singapore)</i>
11:40-12:05	Strategy of Combination Therapy	<i>Man Fung Yuen (The University of Hong Kong, Hong Kong, China)</i>
12:05-12:20	Discussion	
12:20-14:00	Break	

Session 6 Academic Career Workshop

14:00-14:20	How to Design and Conduct a Clinical Study?	<i>Pei-Jer Chen (National Taiwan University, Taiwan)</i>
14:20-14:40	How to Present Orals and Posters in Congress?	<i>Samuel Lee (University of Calgary, Canada)</i>
14:40-15:00	How to Write a Paper?	<i>Paolo Angeli (University of Padova, Italy)</i>
15:00-15:20	Group Dynamics 101: How to Behave in and Lead Small or Large Groups?	<i>Karin King (London School of Economics and Political Science, UK)</i>
15:20-15:40	Discussion	
15:40-15:50	Break	

Session 8 Design of Clinical Trial for MAFLD

15:50-16:10	Risk Stratification Algorithms for Referrals of Patients with MAFLD from Primary to Tertiary Care	<i>Philip Newsome (University of Birmingham, UK)</i>
16:10-16:30	Non-Invasive Tests in Clinical Practice: Are They Useful and Are They Used	<i>Vincent Wong (The Chinese University of Hong Kong, Hong Kong, China)</i>
16:30-16:50	Innovative Clinical Trial Designs for MAFLD	<i>Jacob George (University of Sydney, Australia)</i>
16:50-17:10	Multidisciplinary Management of NASH	<i>Arun Sanyal (Virginia Commonwealth University School of Medicine, USA)</i>
17:10-17:30	Discussion	

DAY 2

Friday, July 16: North & South America
Saturday, July 17: Oceania / Asia / Africa / Europe

ROOM 1

GMT+09:00 (Seoul, Tokyo)

Joint 2 IASL & South America	
07:10-07:30	Long-Term Albumin Administration in Patients with Cirrhosis: How Good Is It? <i>Melissa Dirchwolff (Hospital Privado de Rosario, Argentina)</i>
07:30-07:50	Advances in Hepatic Encephalopathy <i>Manuela Merli (Sapienza University of Rome, Italy)</i>
07:50-08:10	Diagnosis and Impact of Sarcopenia in Patients with Cirrhosis <i>Juan Pablo Arab (Pontificia Universidad Catolica de Chile, Chile)</i>
08:10-08:30	Management of Bacterial Infections <i>Sebastian Marciano (Hospital Italiano de Buenos Aires, Argentina)</i>
08:30-08:50	Discussion
08:50-09:00	Break

Session 9 Portal Hypertension in the 21st Century	
09:00-09:20	Where Are We Moving into Prevention and Treatment of Portal Hypertension? <i>Andres Cardenas (University of Barcelona, Spain)</i>
09:20-09:40	Recent Diagnostic Approach for Portal Hyertension <i>Moon Young Kim (Yonsei University Wonju, Korea)</i>
09:40-10:00	Variceal Bleeding - Update in Prevention and Treatment <i>Alexander Nersesov (Kazakh National Medical University, Kazakhstan)</i>
10:00-10:20	Is There a Global Perspective for Early and Elective TIPS-Implantation? <i>Virginia Hernandez-Gea (University of Barcelona, Spain)</i>
10:20-10:40	Discussion
10:40-10:50	Break

Session 11 Complications of Cirrhosis	
10:50-11:10	Cirrhotic Cardiomyopathy: Comparing Old and New Definition Criteria <i>Marcel Razpotnik (Klinikum Klagenfurt am Wörthersee, Austria)</i>
11:10-11:30	Adverse Cardiovascular Events after Liver Transplantation <i>Manhal Izzy (Vanderbilt University Medical Center, USA)</i>
11:30-11:50	Update in Hepatopulmonary Syndrome and Portopulmonary Hypertension <i>Samir Gupta (University of Toronto, Canada)</i>
11:50-12:10	Advances in Hepatorenal Syndrome and Acute Kidney Injury <i>Florence Wong (University of Toronto, Canada)</i>
12:10-12:30	Discussion
12:30-13:30	Lunch Break

Session 12 Management in Fatty Liver Disease	
13:30-13:50	Exercise to Improve Fatty Liver and Portal Hypertension <i>Takumi Kawaguchi (Kurume University, Japan)</i>
13:50-14:10	Nutritional Interventions for Fatty Liver Disease on the West <i>Shira Zelber-Sagi (University of Haifa, Israel)</i>
14:10-14:30	Awareness for Fatty Liver Disease - Are We Making Any Global Progress? <i>Faisal Sanai (King Saud University, Saudi Arabia)</i>
14:30-14:50	Pediatric Fatty Liver Disease and Risk of Adult Complications <i>Henning Grønbaek (Aarhus University, Denmark)</i>
14:50-15:10	Discussion
15:10-15:20	Break

15:20-15:50	Presidential Lecture <i>Kwang-Hyub Han (NECA, Korea)</i>
15:50-16:00	Break

Session 13 Alcoholic Liver Disease in the 21 Century	
16:00-16:20	Alcoholic Hepatitis - How Can We Modify the Course? <i>Mark Thursz (Imperial College London, UK)</i>
16:20-16:40	Gut Microbiota and Alcoholic Liver Disease <i>Dong Joon Kim (Hallym University, Korea)</i>
16:40-17:00	Genetic Susceptibility to Alcoholic Liver Damage - Global Perspective <i>Felix Stickel (Hirslanden Private Hospital Group, Switzerland)</i>
17:00-17:20	Alcoholic Liver Damage - Best Practice for Public Health Improvement <i>Jürgen Rehm (University of Toronto, Canada)</i>
17:20-17:40	Discussion
17:40-18:00	Wrap-Up & Closing <i>Markus Peck, President-Elect</i>

DAY 2 Friday, July 16: North & South America
Saturday, July 17: Oceania / Asia / Africa / Europe

Session 10 Non-Invasive Assessment of Liver Fibrosis: A Case Based Approach

09:00-09:20	Non-Alcoholic Fatty Liver Disease	<i>Laurent Castera (University of Paris-VII, France)</i>
09:20-09:40	Chronic Hepatitis B	<i>Seung Up Kim (Yonsei University, Korea)</i>
09:40-10:00	Cirrhosis	<i>Massimo Pinzani (University College London, UK)</i>
10:00-10:20	Assessment of HCC Risk	<i>Henry LY Chan (Union Hospital, Hong Kong, China)</i>
10:20-10:40	Discussion	

Joint 3 IASL & KLCA: HCC - Recent Advances in Prevention and Treatment

13:00-13:15	The Changing Global Epidemiology and Prevention	<i>Jidong Jia (Capital Medical University, China)</i>
13:15-13:30	AI-Prediction Model of HCC in Patients with Chronic Hepatitis B	<i>Jeong-Hoon Lee (Seoul National University, Korea)</i>
13:30-13:45	Tenofovir vs. Entecavir for the Prevention of HCC	<i>Sung Won Lee (The Catholic University of Korea, Korea)</i>
13:45-14:00	HCC Surveillance and Diagnosis in 2021	<i>Mindie H. Nguyen (Stanford University, USA)</i>
14:00-14:15	Imaging Diagnosis of Macrotrabecular-Massive HCC	<i>Hyungjin Rhee (Yonsei University, Korea)</i>
14:15-14:30	Application of AI in HCC Treatment	<i>Gwang Hyeon Choi (Seoul National University, Korea)</i>
14:30-14:45	Pursuing Efficacious Combination Treatment for HCC	<i>Ann-Lii Cheng (National Taiwan University, Taiwan)</i>
14:45-15:00	Sequential Treatment for Advanced HCC based on Real-World-Data	<i>Masatoshi Kudo (Kindai University, Japan)</i>
15:00-15:20	Discussion	